ARS Pharmaceuticals
SPRY
Insider trades and stock quote 2024-2026
All insider trades at ARS Pharmaceuticals
| Date |
Type |
Insider |
Position |
Ø-Price |
Volume |
|
6/12/2026
|
Sell |
Fitzpatrick, Alexander A. |
Chief Legal Officer |
$10.0 |
$33,550 |
|
6/12/2026
|
Sell |
Karas, Eric |
Chief Commercial Officer |
$10.0 |
$250,000 |
|
11/13/2025
|
Sell |
Dorsey, Brian |
Chief Operating Officer |
$8.7 |
$190,050 |
|
11/12/2025
|
Sell |
Chakma, Justin |
Chief Business Officer |
$8.9 |
$1,476,147 |
|
8/21/2025
|
Sell |
Scott, Kathleen D. |
Chief Financial Officer |
$15.0 |
$187,500 |
|
8/21/2025
|
Sell |
Lowenthal, Richard E. |
PRESIDENT AND CEO |
$14.5 |
$724,345 |
|
8/20/2025
|
Sell |
Tanimoto, Sarina |
CHIEF MEDICAL OFFICER |
$14.1 |
$530,626 |
|
8/19/2025
|
Sell |
Tanimoto, Sarina |
CHIEF MEDICAL OFFICER |
$14.0 |
$173,130 |
|
7/1/2025
|
Sell |
Karas, Eric |
Chief Commercial Officer |
$17.0 |
$254,861 |
|
6/27/2025
|
Sell |
Flynn, James E. |
Ten Percent Owner |
$18.5 |
$13,663,151 |
|
6/18/2025
|
Sell |
Karas, Eric |
Chief Commercial Officer |
$16.0 |
$240,000 |
|
5/20/2025
|
Sell |
Scott, Kathleen D. |
Chief Financial Officer |
$14.1 |
$705,165 |
|
5/20/2025
|
Sell |
Saunders, Brent L. |
Director |
$14.3 |
$1,710,024 |
|
5/20/2025
|
Sell |
Fitzpatrick, Alexander A. |
Chief Legal Officer |
$14.1 |
$1,451,513 |
|
4/7/2025
|
Sell |
Shawver, Laura |
Director |
$12.3 |
$615,075 |
|
3/20/2025
|
Sell |
Karas, Eric |
Chief Commercial Officer |
$14.0 |
$140,000 |
|
3/6/2025
|
Sell |
Shawver, Laura |
Director |
$11.2 |
$556,046 |
|
3/5/2025
|
Sell |
Shawver, Laura |
Director |
$11.0 |
$4,400 |
|
2/3/2025
|
Sell |
Shawver, Laura |
Director |
$12.3 |
$615,565 |
|
1/6/2025
|
Sell |
Shawver, Laura |
Director |
$11.1 |
$555,065 |
|
12/17/2024
|
Sell |
Lowenthal, Richard E. |
PRESIDENT AND CEO |
$11.7 |
$1,167,100 |
|
12/17/2024
|
Sell |
Tanimoto, Sarina |
CHIEF MEDICAL OFFICER |
$11.7 |
$1,167,100 |
|
12/13/2024
|
Sell |
Chakma, Justin |
Chief Business Officer |
$12.1 |
$328,969 |
|
12/12/2024
|
Sell |
Dorsey, Brian |
Chief Operating Officer |
$12.3 |
$307,433 |
|
12/12/2024
|
Sell |
Chakma, Justin |
Chief Business Officer |
$12.3 |
$1,439,124 |
|
12/11/2024
|
Sell |
Dorsey, Brian |
Chief Operating Officer |
$12.4 |
$186,426 |
|
12/10/2024
|
Sell |
Lowenthal, Richard E. |
PRESIDENT AND CEO |
$13.2 |
$1,316,420 |
|
12/10/2024
|
Sell |
Tanimoto, Sarina |
CHIEF MEDICAL OFFICER |
$13.2 |
$1,316,420 |
|
12/10/2024
|
Sell |
Chakma, Justin |
Chief Business Officer |
$13.2 |
$657,625 |
|
12/6/2024
|
Sell |
Chakma, Justin |
Chief Business Officer |
$14.2 |
$711,615 |
|
12/5/2024
|
Sell |
Chakma, Justin |
Chief Business Officer |
$14.1 |
$701,642 |
|
12/4/2024
|
Sell |
Karas, Eric |
Chief Commercial Officer |
$14.0 |
$87,962 |
|
12/4/2024
|
Sell |
Shawver, Laura |
Director |
$13.7 |
$203,109 |
|
12/4/2024
|
Sell |
Chakma, Justin |
Chief Business Officer |
$14.0 |
$627,944 |
|
12/3/2024
|
Sell |
Shawver, Laura |
Director |
$13.3 |
$1,166,897 |
|
12/3/2024
|
Sell |
Chakma, Justin |
Chief Business Officer |
$13.2 |
$593,402 |
|
12/2/2024
|
Sell |
Karas, Eric |
Chief Commercial Officer |
$14.1 |
$52,461 |
|
12/2/2024
|
Sell |
Shawver, Laura |
Director |
$14.0 |
$1,318,745 |
|
12/2/2024
|
Sell |
Chakma, Justin |
Chief Business Officer |
$13.7 |
$615,218 |
|
11/27/2024
|
Sell |
Chakma, Justin |
Chief Business Officer |
$14.4 |
$359,750 |
|
11/26/2024
|
Sell |
Chakma, Justin |
Chief Business Officer |
$14.0 |
$592,570 |
|
11/25/2024
|
Sell |
Chakma, Justin |
Chief Business Officer |
$14.0 |
$459,422 |
|
11/19/2024
|
Sell |
Tanimoto, Sarina |
CHIEF MEDICAL OFFICER |
$14.0 |
$1,394,960 |
|
11/19/2024
|
Sell |
Lowenthal, Richard E. |
PRESIDENT AND CEO |
$14.0 |
$1,394,960 |
|
11/12/2024
|
Sell |
Flynn, James E. |
Ten Percent Owner |
$17.5 |
$609,064 |
|
11/12/2024
|
Sell |
Lowenthal, Richard E. |
PRESIDENT AND CEO |
$17.2 |
$1,684,642 |
|
11/12/2024
|
Sell |
Tanimoto, Sarina |
CHIEF MEDICAL OFFICER |
$17.2 |
$1,684,642 |
|
11/11/2024
|
Sell |
Flynn, James E. |
Ten Percent Owner |
$17.8 |
$9,534,642 |
All information without guarantee! No recommendation/consultation! © U.S. Securities and Exchange Commission (SEC)
Free Updates via Email
Please confirm your email address